ARTICLE | Product Development
Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise
Sanofi’s new trispecific technology could provide a growth platform for the pharma’s cancer franchise
November 23, 2019 2:07 AM UTC
Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron.
Sanofi (Euronext:SAN; NYSE:SNY) has been striving to expand its cancer franchise as its relationship with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) winds down...